Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

September 30, 2027

Conditions
Psychological Distress
Interventions
DRUG

Psilocybin

Participants randomized to the psilocybin microdosing intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of psilocybin daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.

DRUG

Placebo

Participants randomized to the placebo intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of placebo daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.

Trial Locations (7)

Unknown

William Osler Health System, Brampton

Providence Care Hospital, Kingston

St. Joseph's Healthcare, London

South Lake Regional Health Centre, Newmarket

Bruyere Health, Ottawa

The Ottawa Hospital, Ottawa

McGill University Health Centre, Montreal

All Listed Sponsors
lead

Bruyère Health Research Institute.

OTHER